



**ROTH** Capital Partners



## ROTH Capital Partners Acts as Sole Book-Running Manager for \$7.8 Million Follow-On Offering for NeoStem (NBS)

### Client Information

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that enable people to donate and store their own (autologous) stem cells for potential personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology, which uses very small embryonic-like stem cells shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. (Source: Company Press Release).

### Transaction Information

On February 16, 2010, NeoStem, Inc. (NBS) announced an underwritten public offering of 5,000,000 shares of its common stock at a per share price of \$1.35. On February 18, 2010 ROTH exercised the over-allotment option of 750,000 shares to bring the total transaction value to \$7.8 million. The offering of the shares was made pursuant to a registration statement previously filed with the Securities and Exchange Commission. ROTH Capital Partners acted as the sole book-running manager of the offering.

### ROTH Capital Partners

ROTH is a full service investment banking firm dedicated to advising public and private emerging growth companies. Headquartered in Newport Beach, California, ROTH offers a wide array of services to both corporate and institutional clients including: initial public offerings, follow-ons, mergers and acquisitions, SPACs, PIPEs, private placements, investment research and institutional sales and trading.

### For recent news about ROTH and upcoming events please visit

ROTH Press Room

ROTH Upcoming Conferences & Events



For more information on how ROTH can help you, please contact:

### Investment Banking

**Lisa Walters**  
Managing Director  
858-509-2501  
lwalters@roth.com

**George Zorbas**  
Vice President  
858-509-2505  
gzorbas@roth.com

### Equity Capital Markets

**Aaron Gurewitz**  
Head of Equity Capital Markets  
949-720-5703  
agurewitz@roth.com

**Lou Ellis**  
Sr. Vice President  
949-720-5739  
lellis@roth.com

**Nazan Akdeniz**  
Sr. Vice President  
949-720-5740  
nakdeniz@roth.com

The material, information and facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2010.

ROTH Capital Partners, LLC. | 24 Corporate Plaza, Newport Beach, CA 92660 | 800.678.9147 | www.roth.com | Member SIPC/FINRA